Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleotides

Neuromuscular Disorders

Volumn 9, Issue 5, 1999, Pages 330-338

  Wilton, Stephen D ^a   Lloyd, Frances ^a   Carville, Kylie ^a   Fletcher, Sue ^a   Honeyman, Kaite ^a   Agrawal, Sudhir ^b   Kole, Ryszard ^c  

^a Australian Neuromuscular Res Inst   (Australia)

^b HYBRIDON INC   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Antisense oligonucleotides; Duchenne muscular dystrophy; Dystrophin pre mRNA; Genetic therapy; Induced exon skipping; mdx mouse

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; DYSTROPHIN; MESSENGER RNA;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DUCHENNE MUSCULAR DYSTROPHY; GENE THERAPY; IN VITRO STUDY; MOUSE; MYOBLAST; NONHUMAN; NONSENSE MUTATION; PRIORITY JOURNAL;

ALTERNATIVE SPLICING; AMINO ACID SEQUENCE; ANIMALS; BASE SEQUENCE; CELL LINE; DYSTROPHIN; EXONS; MICE; MICE, INBRED C57BL; MICE, INBRED MDX; MUSCULAR DYSTROPHY, ANIMAL; MUTATION; OLIGONUCLEOTIDES, ANTISENSE; RNA PRECURSORS; RNA PROCESSING, POST-TRANSCRIPTIONAL; RNA, MESSENGER;

EID: 0033044501     PISSN: 09608966     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-8966(99)00010-3     Document Type: Article

References (39)

1. Koenig M., Hoffman E., Moyer M.et al. The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion. Am J Hum Genet. 45:1989;498-506.
2. Monaco A., Bertelson C., Liechti-Gallati S., Moser H., Kunkel L. An explanation for the phenotypic differences between patients bearing partial deletions of the dmd locus. Genomics. 2:1988;90-95.
3. Bulfield G., Siller W., Wight P., Moore K. X chromosome-linked muscular dystrophy (mdx) in the mouse. Proc Natl Acad Sci USA. 81:1984;1189-1192.
4. Partridge T. Myoblast transfer: a possible therapy for inherited myopathies? Muscle Nerve. 14:1991;197-212.
5. Morgan J. Cell and gene therapy in Duchenne muscular dystrophy. Hum Gene Ther. 5:1994;165-173.
6. Sicinski P., Geneg Y., Ryder-Cook A., Barnard E., Darlison M., Barnard P. The molecular basis of muscular dystrophy in the mdx mouse: a point mutation. Science. 244:1989;1578-1580.
7. Hoffman E., Morgan J., Watkins S., Partridge T. Somatic reversion/suppression of the mouse mdx phenotype in vivo. J Neurol Sci. 9:1990;9-25.
8. Nicholson L., Davidson K., Johnson M.et al. Dystrophin in skeletal muscle: II. Immunoreactivity in patients with Xp21muscular dystrophy. J Neurol Sci. 94:1989;137-146.
9. Fanin M., Daniele G., Cadaldini M., Miorin M., Vitiello L., Angelini C. Dystrophin-positive fibers in Duchenne dystrophy: origin and correlation to clinical course. Muscle Nerve. 18:1995;1115-1120.
10. Klein C., Coovert D., Bulman D., Ray P., Mendell J., Burghes A. Somatic reversion/suppression in Duchenne muscular dystrophy (DMD): evidence supporting a frame-restoring mechanism in rare dystrophin-positive fibers. Am J Hum Genet. 50:1992;950-959.
11. Wallgren-Pettersson C., Jasani B., Rosser L., Lazarou L., Nicholson L., Clarke A. Immunological evidence for second or somatic mutations as the underlying cause of dystrophin expression by isolated fibers in Xp21 muscular dystrophy of Duchenne-type severity. J Neurol Sci. 118:1993;56-63.
12. Wilton S., Dye D., Laing N. Dystrophin gene transcripts skipping the mdx mutation. Muscle Nerve. 20:1997;728-734.
13. Agrawal S. Antisense oligonucleotides as antiviral agents. Trends Biotechnol. 10:1992;152-158.
14. Ghosh M., Ghosh K., Cohen J. Phosphorothioate phosphodiester oligonucleotide co-polymers assessment for antisense application. Anticancer Drug Des. 8:1993;15-32.
15. Maher L., Dervan P., Wold B. Analysis of promoter-specific repressions by triple-helical DNA complexes in a eukaryotic cell-free transcription system. Biochemistry. 31:1992;70-81.
16. Hanvey J., Peffer N., Bisi J.et al. Antisense and antigene properties of peptide nucleic acids. Science. 258:1992;1481-1485.
17. Sierakowska H., Sambade M., Agrawal S., Kole R. Repair of thalassemic human beta-globin mRNA in mammalian cells by antisense oligonucleotides. Proc Natl Acad Sci USA. 93:1996;12840-12844.
18. Sierakowska H., Montague M., Agrawal S., Kole R. Restoration of beta-globin gene expression in mammalian cells by antisense oligonucleotides that modify the aberrant splicing patterns of thalassemic pre-mRNAs. Nucleosides Nucleotides. 16:1997;1173-1182.
19. Roberts R., Coffer A., Bobrow M., Bentley D. Exon structure of the human dystrophin gene. Genomics. 16:1993;536-538.
20. Pramono Z., Takeshima Y., Alimsardjono H., Ishii A., Takeda S., Matsuo M. Induction of exon skipping of the dystrophin transcript in lymphoblastoid cells by transfecting on antisense oligodeoxynucleotide complementary to an exon recognition sequence. Biochem Biophys Res Commun. 226:1996;445-449.
21. Dunckley M., Manoharan M., Villiet P., Eperon I., Dickson G. Modification of splicing in the dystrophin gene in cultured mdx muscle cells by antisense oligoribonucleotides. Hum Mol Genet. 5:1998;1083-1090.
22. Shapiro M., Senepathy P. RNA splice junctions of different classes of eukaryotes:sequence statistics and functional implications in gene expression. Nucleic Acids Res. 15:1987;7155-7174.
23. Tennyson C., Shi Q., Worton R. Stability of the human dystrophin transcript in muscle. Nucleic Acids Res. 24:1996;3059-3064.
24. Hoffman E., Fischbeck K., Brown R.et al. characterization of dystrophin in muscle-biopsy specimens from patients with Duchenne's or Becker's muscular dystrophy. N Engl J Med. 31:1988;1363-1368.
25. Nicholson L., Johnson M., Bushby K., Gardner-Medwin D. Functional significance of dystrophin positive fibres in Duchenne muscular dystrophy. Arch Dis Child. 68:1993;632-636.
26. Legum C., Shomrat R., Glassner M., Shiloh Y. A molecular survey of Israeli Duchenne and Becker muscular dystrophy patients. Biomed Biopharm. 48:1994;359-364.
27. Koenig M., Monaco A., Kunkel L. The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein. Cell. 53:1989;219-228.
28. Gorecki D., Monaco A., Derry J., Walker A., Barnard E., Barnard P. Expression of four alternative dystrophin transcripts in brain regions regulated by different promoters. Hum Mol Genet. 1:1992;505-510.
29. Boyce F., Beggs A., Feener C., Kunkel L. Dystrophin is transcribed in brain from a distant upstream promoter. Proc Natl Acad Sci USA. 88:1991;1276-1280.
30. D'Souza V., Thi Man N., Morris G., Karges W., Pillers D., Ray P. A novel dystrophin isoform is required for normal retinal electrophysiology. Hum Mol Genet. 4:1995;837-842.
31. Lidov H., Selig S., Kunkel L. Dp140: a novel 140 kDa CNS transcript from the dystrophin locus. Hum Mol Genet. 4:1995;329-335.
32. Byers T., Lidov H., Kunkel L. An alternative dystrophin transcript specific to peripheral nerve. Nat Genet. 4:1995;77-81.
33. Uchino M., Tokunaga M., Mita S.et al. PCR and immunocytochemical analyses of dystrophin-positive fibers in Duchenne muscular dystrophy. J Neurol Sci. 129:1995;44-50.
34. Maquat L. When cells stop making sense: effects of nonsense codons on RNA metabolism in vertebrate cells. RNA. 1:1995;453-465.
35. Tennyson C., Klamut H., Worton R. The human dystrophin gene requires 16 hours to be transcribed and is cotranscriptionally spliced. Nat Genet. 9:1995;184-190.
36. Kessler O., Jiang Y., Chasin L. Order of intron removal during splicing of endogenous adenine phosphoribosyltransferase and dihydrofolate reductase pre-mRNA. Mol Cell Biol. 13:1993;6211-6222.
37. Danko I., Wolff J. Direct gene transfer into muscle. Vaccine. 12:1994;1499-1502.
38. Furdon P., Dominski Z., Kole R. RNase H cleavage of RNA hybridized to oligonucleotides containing methylphosphonate phosphorothioate and phosphodiester bonds. Nucleic Acids Res. 17:1989;9193-9204.
39. Gorman L., Suter D., Emerick V., Schumperli D., Kole R. Stable alteration of pre-mRNA splicing patterns by modified U7 small nuclear RNAs. Proc Natl Acad Sci USA. 95:1998;4929-4934.